These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 4011664)

  • 1. [Improvement of the dissolution behavior of problem drugs. 4. Differential thermal analysis of iomeglamic acid-succinic acid embedding].
    Fahr F; Kala H; Masthoff F
    Pharmazie; 1985 Apr; 40(4):270-1. PubMed ID: 4011664
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement of the dissolution behavior of problem drugs. 3. X-ray diffraction measurement of iomeglamic acid/succinic acid solid dispersions].
    Fahr F; Kala H; Pollandt P
    Pharmazie; 1985 Feb; 40(2):127-8. PubMed ID: 4001148
    [No Abstract]   [Full Text] [Related]  

  • 3. [The improvement of solubility behavior of problem drugs. 2. Solubility behavior of slow dissolving products of iomeglamic acid and succinic acid].
    Fahr F; Kala H; Scharrenweber F
    Pharmazie; 1985 Jan; 40(1):60-1. PubMed ID: 3991791
    [No Abstract]   [Full Text] [Related]  

  • 4. [Improvement of the dissolution behavior of problem drugs. 11. DTA iomeglamic-PVP 25 copreciptates].
    Fahr F; Kala H; Masthoff F; Fries G
    Pharmazie; 1986 Jul; 41(7):517. PubMed ID: 3774866
    [No Abstract]   [Full Text] [Related]  

  • 5. [Improvement of the solubility of problem drugs. 17. Processing of iomeglamic acid/methylcellulose coprecipitates in tablets].
    Fahr F; Kala H; Hückel T; Fries G
    Pharmazie; 1988 Mar; 43(3):216. PubMed ID: 3380870
    [No Abstract]   [Full Text] [Related]  

  • 6. [Improvement of the solubility behavior of problem drugs. 20. The effect of pharmaceutical excipients on the wetability of iomeglamic acid].
    Fahr F; Zessin G; Kala H; Fries G
    Pharmazie; 1989 Aug; 44(8):576-7. PubMed ID: 2594830
    [No Abstract]   [Full Text] [Related]  

  • 7. [The improvement of solubility behavior of problem drugs. 7. Iomeglamic acid-mannitol-melting viscosity products].
    Fahr F; Kala H; Pollandt P; Zessin G
    Pharmazie; 1985 Oct; 40(10):733-4. PubMed ID: 3936061
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improvement of the solubility behavior of problem drugs. 9. In vitro absorption studies using melting solidification products of iomeglamic acid].
    Fahr F; Neubert R; Fürst W; Kala H; Masthoff F
    Pharmazie; 1986 Dec; 41(12):855-6. PubMed ID: 3575388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Improvement of the solubility of problem drugs. 1. Production of iomeglamic acid fused and solidified products].
    Fahr F; Kala H; Pollandt P; Wenzel U; Masthoff F
    Pharmazie; 1985 Jun; 40(6):408-9. PubMed ID: 4034650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvement of the solubility of problem drugs. 18. Iomeglamic acid-PVA effervescent powder].
    Fahr F; Kala H; Fries G; Helbig G
    Pharmazie; 1988 Mar; 43(3):217. PubMed ID: 3380871
    [No Abstract]   [Full Text] [Related]  

  • 11. [Improvement of the solubility of problem drugs. 15. Alteration of iomeglamic acid-methylcellulose (MH 300)-PEG 6000 coprecipitates].
    Fahr F; Kala H; Pollandt P; Fries G; Hückel T
    Pharmazie; 1987 Aug; 42(8):552-3. PubMed ID: 3432340
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improvement of the solubility of problem drugs. 15. X-ray diffraction of iomeglamic acid-methylcellulose (MH 300)-PEG 6000-coprecipitate].
    Fahr F; Kala H; Pollandt P; Hückel T; Fries G
    Pharmazie; 1987 Aug; 42(8):554. PubMed ID: 3432342
    [No Abstract]   [Full Text] [Related]  

  • 13. [Analysis of iomeglamic acid (Falignost)].
    Pfeifer S; Schäffner J; Bornschein I
    Pharmazie; 1972 Jun; 27(6):396-403. PubMed ID: 5082266
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of dioctyl sodium sulphosuccinate (DSS) on the dissolution rate of propyphenazone from tablets.
    Djurić M; Djurić Z; Jovanović M
    Pharmazie; 1988 Dec; 43(12):873-4. PubMed ID: 2470115
    [No Abstract]   [Full Text] [Related]  

  • 15. Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study.
    Siepe S; Herrmann W; Borchert HH; Lueckel B; Kramer A; Ries A; Gurny R
    J Control Release; 2006 May; 112(1):72-8. PubMed ID: 16476499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenine succinic acid and adenylsuccinic acid from mammalian liver: isolation and identification.
    JOKLIK WK
    Biochem J; 1957 Jun; 66(2):333-41. PubMed ID: 13445694
    [No Abstract]   [Full Text] [Related]  

  • 17. The occurrence of adenine- and adenyl-succinic acid in mammalian liver.
    JOKLIK WK
    Biochim Biophys Acta; 1956 Oct; 22(1):211-2. PubMed ID: 13373878
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Presence of homarine, taurocyamine, choline, lysine and other amino acids, also of succinic acid, in the marine snail, Arenicola marina].
    ACKERMANN D
    Hoppe Seylers Z Physiol Chem; 1955 Nov; 302(2-3):80-6. PubMed ID: 13306162
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzymic micro-determination of succinate and fumarate in tissue homogenates.
    BRIL C
    Biochim Biophys Acta; 1954 Oct; 15(2):258-62. PubMed ID: 13208691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.